Concentration in Production Facilities in Hyuga City, Miyazaki Prefecture
First written in FY2016. 23 of 28 entries say "Restated". Latest entry: FY2025.
The whole theme swung hardest in 2020: 5 of 17 companies on the "Worse" side.
5 other companies' latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「The Group is promoting risk diversification measures, including increasing production and shipments at Medikit Vietnam Co., Ltd., using a production building at the coastal Hyuga plant that also serves as a tsunami evacuation building, expanding the inland Hyuga No. 2 Plant, expanding sterilization facilities and a distribution warehouse at the Hyuga No. 3 Plant, and holding product inventory at the Sakura distribution warehouse, which primarily serves eastern Japan.」
The measures have been made more specific by combining production in Vietnam, expansion of the Hyuga No. 2 Plant, expansion of sterilization facilities and a distribution warehouse at the Hyuga No. 3 Plant, and inventory at the Sakura distribution warehouse. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2024-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2023MitigatedAnnual report
「The Group is promoting risk diversification measures, including increasing production and shipments at Medikit Vietnam Co., Ltd., using a production building at the coastal Hyuga plant that also serves as a tsunami evacuation building, expanding the inland Hyuga No. 2 Plant, establishing a sterilization facility at the Hyuga No. 3 Plant, and holding product inventory at the Sakura distribution warehouse, which primarily serves eastern Japan.」
In addition to the existing measures of production in Vietnam, the production building at the Hyuga plant, the sterilization facility at the Hyuga No. 3 Plant, and inventory at the Sakura warehouse, the expansion of the Hyuga No. 2 Plant is specifically identified as a risk diversification measure. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2023-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2022RestatedAnnual report
「The Group is promoting risk diversification measures, including increasing production and shipments at Medikit Vietnam Co., Ltd., using a production building at the coastal Hyuga plant that also serves as a tsunami evacuation building, establishing a sterilization facility at the inland Hyuga No. 3 Plant, and holding product inventory at the Sakura distribution warehouse, which primarily serves eastern Japan.」
Diversification measures to address the concentration risk at production sites continue, including production in Vietnam, the production building at the Hyuga plant, the sterilization facility at the Hyuga No. 3 Plant, and inventory at the Sakura warehouse. - FY2022-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2022-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2022-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2021MitigatedAnnual report
「The Group is promoting risk diversification measures, including increasing production and shipments at Medikit Vietnam Co., Ltd., constructing and operating a new multistory production building at the Hyuga plant, and holding product inventory at the Sakura distribution warehouse, which primarily serves eastern Japan.」
Several diversification measures are being implemented, including increased production and shipments in Vietnam, operation of the new production building at the Hyuga plant, and inventory at the Sakura warehouse. - FY2021-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2021-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2020MitigatedAnnual report
「The Group is promoting risk diversification measures, including increasing production and shipments at Medikit Vietnam Co., Ltd., constructing a new multistory production building at the Hyuga plant, and holding product inventory at the Sakura distribution warehouse, which primarily serves eastern Japan.」
Several specific diversification measures are identified in response to the concentration risk at the Hyuga production site, including increased production and shipments in Vietnam, a new production building, and inventory at the Sakura warehouse. - FY2020-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2020-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2020-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2019-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2019-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2019-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2018RestatedAnnual report
「Nearly all products sold by the Group are developed and manufactured by Togo Medikit Co., Ltd., the Group's consolidated subsidiary. Togo Medikit Co., Ltd.'s main manufacturing plant is located in Hyuga, Miyazaki Prefecture. If the plant were damaged by a disaster such as an earthquake, typhoon, or fire, the Group's results could be affected.」
The risk related to concentration at Togo Medikit and the production operations in Hyuga, Miyazaki Prefecture, continues. - FY2018-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2018-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2018-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no new developments or significant changes. - FY2017-Q3RestatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2017-Q1RestatedAnnual report
「During the cumulative first quarter under review, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The risk related to the concentration of production operations in Hyuga, Miyazaki Prefecture, is reaffirmed through a comprehensive statement that there have been no significant changes. - FY2016First statedAnnual report
「Nearly all products sold by the Group are developed and manufactured by Togo Medikit Co., Ltd., the Group's consolidated subsidiary. Togo Medikit Co., Ltd.'s main manufacturing plant is located in Hyuga, Miyazaki Prefecture. If the plant were damaged by a disaster such as an earthquake, typhoon, or fire, the Group's results could be affected.」
The concentration of product development and manufacturing at Togo Medikit and its main plant in Hyuga is identified as a risk.